ZIP Diagnostics Pty Ltd., Collingwood, VIC 3066, Australia.
Department of Medicine, University of Melbourne, Melbourne, VIC 3010, Australia.
Viruses. 2022 Jun 15;14(6):1311. doi: 10.3390/v14061311.
The COVID-19 pandemic has resulted in an unprecedented global demand for in vitro diagnostic reagents. Supply shortages and hoarding have impacted testing capacity which has led to inefficient COVID-19 case identification and transmission control, predominantly in developing countries. Traditionally, RNA extraction is a prerequisite for conducting SARS-CoV-2 nucleic acid amplification tests (NAAT); however, simplified methods of sample processing have been successful at bypassing typical nucleic acid extraction steps, enabling extraction-free SARS-CoV-2 NAAT workflows. These methods involve chemical and physical approaches that are inexpensive and easily accessible alternatives to overcome extraction kit supply shortages, while offering acceptable test performance. Here we provide an overview of three main sample preparation strategies that have been shown to facilitate extraction-free SARS-CoV-2 NAATs.
COVID-19 大流行导致对体外诊断试剂的需求空前增长。供应短缺和囤积影响了检测能力,导致 COVID-19 病例的识别和传播控制效率低下,主要是在发展中国家。传统上,RNA 提取是进行 SARS-CoV-2 核酸扩增检测(NAAT)的前提;然而,简化的样本处理方法已成功绕过典型的核酸提取步骤,实现了无需提取的 SARS-CoV-2 NAAT 工作流程。这些方法涉及廉价且易于获取的化学和物理方法,可替代提取试剂盒的供应短缺,同时提供可接受的测试性能。在这里,我们提供了三种已被证明可促进无需提取的 SARS-CoV-2 NAAT 的主要样本制备策略的概述。